ERCC1 and non-small cell lung carcinoma: The authors also demonstrated that excision repair cross-complementation group 1 (ERCC1) is a target of miR-138, suggesting a crucial role of this miRNA in the acquirement of cisplatin resistance in NSCLC (81).